2019
DOI: 10.7759/cureus.4185
|View full text |Cite
|
Sign up to set email alerts
|

A Review of Novel Antidepressants: A Guide for Clinicians

Abstract: This review article aims to provide insight into the mechanisms of action, pharmacokinetics, clinical efficacy, safety and tolerability of four novel antidepressants including desvenlafaxine, vortioxetine, vilazodone, and levomilnacipran. Following keywords are used in PubMed and Scopus to search for relevant articles: (depression) AND (psychopharmacology OR desvenlafaxine OR levomilnacipran OR vortioxetine OR vilazodone). Patients with a lack of effectiveness or tolerability to certain antidepressants may get… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
35
0
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 44 publications
(37 citation statements)
references
References 46 publications
(76 reference statements)
0
35
0
2
Order By: Relevance
“…Depression was the leading cause of disability in the world, and suicide was the 10th leading cause of death in 2015 [2]. Major depressive disorder (MDD) is the fourth cause of disability around the world and is estimated to be the second leading cause of disability by 2020 [4]. Over the past 20 years the prevalence of child and adolescent mental disorders in high-income countries has not changed despite increased investment in MH services.…”
Section: Fig-1: Changing the Conversation About Mental Health (Mh) [1]mentioning
confidence: 99%
“…Depression was the leading cause of disability in the world, and suicide was the 10th leading cause of death in 2015 [2]. Major depressive disorder (MDD) is the fourth cause of disability around the world and is estimated to be the second leading cause of disability by 2020 [4]. Over the past 20 years the prevalence of child and adolescent mental disorders in high-income countries has not changed despite increased investment in MH services.…”
Section: Fig-1: Changing the Conversation About Mental Health (Mh) [1]mentioning
confidence: 99%
“…Selective serotonin‐reuptake inhibitors (SSRI) and serotonin‐norepinephrine reuptake inhibitors (SNRI) are currently the first‐line antidepressants recommended for the treatment of depression, due to their efficacy and low risk of adverse events 9 . The mechanism of action of SSRI includes inhibiting the reuptake of serotonin, whereas the mechanism of action of SNRI involves inhibiting the reuptake of both serotonin and norepinephrine, increasing the concentration of these neurotransmitters within the synapse 10,11 . When treatments with SSRI or SNRI fail, the selection of a second‐line class of antidepressants with a different mode of action is recommended 9,11 .…”
Section: Introductionmentioning
confidence: 99%
“…2014-2018 yılları arasında yazılan tüm SSGİ/SNGİ e-reçetelerinin sayısı reçetelerdeki toplam ilaç sayılarına göre karşılaştırıldığında %95,0'inin sadece tek bir SSGİ/ SNGİ içerdiği, %4.9'unun ise birden fazla SSGİ/SNGİ (14,18,21). Literatürle uyumlu olarak SSGİ'lerin reçete edilme oranlarının SNGİ'lerden daha fazla artış göstermesi, uluslararası kılavuzlarda SSGİ'lerin ilk tercih AD olarak önerilmeleri, tolerabilitelerinin daha iyi olması gibi nedenlere bağlı olabilir (22). 2014-2018 yılları arasındaki tüm reçetelere bakıldığında en sık reçete edilen SSGİ/SNGİ'nin sertralin olduğu görüldü.…”
Section: Ssgi̇/sngi̇ Reçetelerindeki Toplam Ilaç Sayıları Ve Kombinasyounclassified
“…Duloksetin, sitalopram ve venlafaksinin daha fazla kombine edilmesi ise bu ilaçların çoğunlukla ikinci SSGİ/SNGİ olarak tercih edildiğini göstermektedir. Duloksetin ve venlafaksinin kombinasyon oranlarının yüksek olması, SSGİ'lerin ilk tercih olarak yazıldığı ve yeterli klinik etkinliğin alınamadığı hastalarda SNGİ grubunda yer alan AD'ların eklenerek tedavinin yeniden düzenlenmesi ile açıklanabilir (22). Sitalopramın diğer SSGİ grubundaki AD'lardan daha sık kombine edilmesi ya da tek ilaç olarak daha az kullanılması ise, sitalopramın kimyasal olarak rasemik karışım şeklinde (R-, S-) formüle edilmesi nedeniyle esas etkinliği oluşturan S-formunun (essitalopram) tercih edilmesi olabilir (24).…”
Section: Sertralin Essitalopram Venlafaksin Fluoksetin Paroksetin Situnclassified